NCT06467617View on ClinicalTrials.gov

Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC

PHASE2RecruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

August 14, 2024

Primary Completion Date

August 1, 2026

Study Completion Date

March 1, 2027

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

Adebrelimab plus albumin-bound paclitaxel, carboplatin and recaticimab

"Adebrelimab (1200 mg,IV, D1, Q3W) +~albumin-bound paclitaxel (260 mg/m2, IV, divided by D1,8,Q3W) +~carboplatin (AUC 5mg/mL/min, IV, D1,Q3W) +~recaticimab (150 mg, SC, D1,Q3W)~21-day cycle"

Trial Locations (1)

101125

RECRUITING

Beijing Chest Hospital, Beijing

All Listed Sponsors
lead

Beijing Chest Hospital, Capital Medical University

OTHER